GLP-1 Drugs Linked to 25% Lower Amputation Risk in Patients with Severe Leg Artery Disease | Research

The takeaway

Diabetic patients with chronic limb-threatening ischemia who took GLP-1 receptor agonists had 25% fewer major amputations, plus lower rates of death and heart attacks over 5 years.

25.5% lower major amputation risk
GLP-1 receptor agonist users vs non-users among 15,743 propensity-matched diabetic patients with chronic limb-threatening ischemia over 5 years

What the researchers found

Among 139,173 diabetic patients with chronic limb-threatening ischemia (CLTI), GLP-1 receptor agonist users had significantly lower 5-year rates of major amputation (HR 0.745, 95% CI 0.679–0.816), all-cause mortality, and myocardial infarction compared to non-users after propensity score matching (15,743 patients per group). The reduction in ischemic stroke did not reach statistical significance (p=0.353). These benefits persisted after adjusting for demographics, comorbidities, concurrent medications, and laboratory values.

Why it matters

Chronic limb-threatening ischemia is the most severe form of peripheral artery disease and carries devastating consequences — amputation, heart attack, and death. This is among the first large studies to show that GLP-1 receptor agonists may protect these high-risk patients from limb loss and cardiovascular events, suggesting benefits that extend far beyond blood sugar control.

The numbers in context

n=139,173 total · 17,306 GLP-1RA users · 15,743 matched per group · 91% match rate · major amputation HR 0.745 · mean age 65.4 · 58.9% male · mean follow-up 753.7 days

How the study worked

Retrospective cohort study using the TriNetX real-world clinical data platform. Patients with type 2 diabetes and CLTI were identified and categorized by GLP-1RA prescription. Propensity score matching balanced groups on demographics, comorbidities, medications, and lab values (91% match rate, 15,743 per group). Cox proportional hazards models, Kaplan-Meier curves, and log-rank tests assessed 5-year outcomes.

Who was studied

139,173 U.S. patients with type 2 diabetes and chronic limb-threatening ischemia, with 17,306 on GLP-1 receptor agonists

What this study cannot tell us

Retrospective observational design cannot prove causation. Despite propensity matching, residual confounding from unmeasured variables is possible. GLP-1RA users may have had better access to care or adherence behaviors. The abstract contains incomplete hazard ratio data for some outcomes (all-cause mortality and MI values appear truncated). Stroke benefit was not statistically significant.

How to read the evidence

Very large propensity-matched retrospective cohort study using a real-world clinical database. The sample size (139,173 total) and 91% match rate are strengths, but the observational design cannot establish causation. Residual confounding remains possible.

When this study was published

Published in 2026, this is among the most current evidence on GLP-1 receptor agonists in peripheral vascular disease and addresses a clinically urgent question about limb preservation.

The bigger picture

GLP-1 receptor agonists are already known to reduce cardiovascular events in diabetes, but their effect on the most severe peripheral artery disease has been largely unknown. This study extends the protective signal to CLTI — a population with the highest amputation rates — and suggests that GLP-1 drugs could become part of limb salvage strategies alongside revascularization procedures.

Questions still open

Would a randomized controlled trial confirm the amputation-reduction benefit of GLP-1 receptor agonists in CLTI patients?
What is the mechanism by which GLP-1 drugs protect against limb ischemia — is it anti-inflammatory, vascular, or metabolic?
Should GLP-1 receptor agonists be recommended as standard of care for diabetic patients with CLTI?

Common questions

What is chronic limb-threatening ischemia (CLTI)?

CLTI is the most severe form of peripheral artery disease, where blood flow to the legs is so restricted that tissue starts to die. Without treatment, it typically leads to gangrene and amputation. It affects mostly older adults with diabetes and is associated with very high rates of heart attack, stroke, and death.

How might GLP-1 drugs prevent amputations?

While the exact mechanism isn't fully understood, GLP-1 receptor agonists are known to reduce inflammation, improve blood vessel function, and lower blood sugar — all factors that contribute to peripheral artery disease progression. By addressing multiple risk factors simultaneously, these peptide drugs may slow disease progression enough to prevent the need for amputation.

Read the original research

Benefits of glucagon-like peptide (GLP)-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia.

Vascular medicine (London, England), 31(1), 47-53

View on PubMed ↗Publisher’s paper ↗

Citation

Yahyavi, Ashkan; Zokaei Nikoo, Maedeh; Hussein, Leen; Katara, Aarti; Perez, Jaime A; Shishehbor, Mehdi H. (2026). Benefits of glucagon-like peptide (GLP)-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia.. Vascular medicine (London, England), 31(1), 47-53. https://doi.org/10.1177/1358863X251393107